An interventional study of Blood sample in Hypercholesterolemia, sponsored by Assistance Publique Hopitaux De Marseille. Recruiting at 1 site in France. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-27.
Sponsored by Assistance Publique Hopitaux De Marseille · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies in Hypercholesterolemia with a site in France — 5 open to participants now, 11 under way, 5 of them phase 3. Hypercholesterolemia · France.
Among the 66 studies in Hypercholesterolemia with a site in France, this one is the 36th largest by planned enrollment of the 62 interventional ones that give a count, is one of 4 that started in 2021, is one of 16 with no phase, reaches primary completion later than 1 of the 10 other live ones, and was the 50th registered.
1,180 studies on the registry are indexed under Hypercholesterolemia; 96 are open to participants now.
Browse Hypercholesterolemia studies →5 of the 66 studies in Hypercholesterolemia with a site in France are open now. Recruiting first, the newest first:
Institut Pasteur de Lille · Sites in France
Ages 18–65 · Healthy volunteers
Institut Pasteur de Lille · Sites in France
Ages 18–70 · Healthy volunteers
Centre Hospitalier Universitaire, Amiens · Sites in France
Ages 2–18 · Healthy volunteers
Novartis Pharmaceuticals · Sites in France, United States, Argentina and 20 more countries
Ages 6–11
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 58 Hypercholesterolemia studies recruiting now, 25 (43%) set no upper age limit and 21 (36%) stop at 75 or younger; 10 take children under 18; 12 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 35 · Phase 4 4
First in 2002; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 108 across 979 interventional studies indexed under Hypercholesterolemia.
Median enrollment 300 across the 62 interventional studies, 4,816 across the 4 observational. Of the 53 that completed or were terminated, 29 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 66 have an industry lead sponsor. The 10 most frequent:
Assistance Publique Hopitaux De Marseille is the lead sponsor of 702 studies on the registry; 139 are open to participants now.
Assistance Publique Hopitaux De Marseille has 1 study filed under Hypercholesterolemia — fewer than ten, so there is no comparison to draw.
3 of the studies in Hypercholesterolemia with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT07946458Institut Pasteur de LilleLIPI-PROTECT-1 : Dietary Supplement in Subjects With Moderate Hypercholesterolemia (LPP1) | 2027-01-31 |
| NCT07948226Institut Pasteur de LilleLIPI- PROTECT-2 : Dietary Supplement in Subjects With Moderate Hypercholesterolemia (LPP2) | 2027-03-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 66 studies in Hypercholesterolemia with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Hypercholesterolemia promotes chronic inflammation, endothelial dysfunction, atherosclerosis and is a major risk factor for cardiovascular disease (CVD). Treatment with lipid-lowering drugs (statins, ezetimibe, PCSK9 inhibitors or LDL-apheresis) reduces the risk of major cardiovascular events in proportion to the absolute reduction of LDL-cholesterol (LDL-C). Nevertheless, a better understanding of the effects of hypercholesterolemia on the cardiovascular and immune systems could help identify all the mechanisms responsible for the excess risk of CVD in hypercholesterolemic patients and develop better prevention and treatment strategies.
Adenosine via A2A receptors (A2AR) plays a crucial role in the regulation of the cardiovascular and immune systems.
In this project, the investigators wish :
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For the group of hypercholesterolemic patients :
For the healthy group :
● No cholesterol-modifying therapy.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
volunteers showing no hypercholesterolemia
Biological: Blood sample
patients presenting hypercholesterolemia with no treatment at the time of inclusion
Biological: Blood sample
patients presenting hypercholesterolemia and treated at the time of inclusion
Biological: Blood sample
Blood sampling.
Quantification of A2AR expression in PBMCs
Comparison between hypercholesterolemic patients and healthy volunteers
Time frame: Baseline
Quantification of A2AR expression in PBMCs
Comparison between hypercholesterolemic patients and healthy volunteers
Time frame: 3 months after initiation of treatment
Quantification of A2AR function in PBMC
Comparison between hypercholesterolemic patients and healthy volunteers
Time frame: 3 months after initiation of treatment
Quantification of A2AR function in PBMC
Comparison between hypercholesterolemic patients and healthy volunteers
Time frame: Baseline
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2021 (actual). Primary completion is estimated for Mar 2026, 53 months after the start.
Of 135 non-industry interventional studies with no phase under Hypercholesterolemia, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 36. This study's planned 53 months is above that.
Counting every sponsor, half of 153 studies reached it within 15 months; a quarter within 6 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique Hopitaux De Marseille →